testosterone undecanoate 198 MG Oral Capsule [Jatenzo]
testosterone undecanoate
RxCUI: 2201642
What the CMS Formulary Data Shows for testosterone undecanoate 198 MG Oral Capsule [Jatenzo]
Per the CMS 2026 Part D formulary file, testosterone undecanoate 198 MG Oral Capsule [Jatenzo] (RxNorm concept RXCUI 2201642, generic name testosterone undecanoate) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 4 to Tier 4, with a cross-plan average of Tier 4.
Real-world access to testosterone undecanoate 198 MG Oral Capsule [Jatenzo] depends on utilization management as much as tier placement: 100% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,079 Part D beneficiaries filled testosterone undecanoate 198 MG Oral Capsule [Jatenzo] in 2023, with total plan-and-beneficiary spending of $4,591,544 and an average per-beneficiary annual cost of $4,255.37. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry testosterone undecanoate 198 MG Oral Capsule [Jatenzo] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 4, Non-Preferred
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 100% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,079
- Total spending
- $4,591,544
- Avg per beneficiary
- $4,255.37
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering testosterone undecanoate 198 MG Oral Capsule [Jatenzo]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T4 | Yes | $47.00 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T4 | Yes | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T4 | Yes | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | KEYSTONE HEALTH PLAN EAST, INC. | T4 | Yes | $79.70 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T4 | Yes | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC INSURANCE COMPANY | T4 | Yes | $112.70 | PA |
Frequently Asked Questions
Is testosterone undecanoate 198 MG Oral Capsule [Jatenzo] covered by Medicare Part D?
Yes, testosterone undecanoate 198 MG Oral Capsule [Jatenzo] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is testosterone undecanoate 198 MG Oral Capsule [Jatenzo] on Medicare Part D plans?
testosterone undecanoate 198 MG Oral Capsule [Jatenzo] averages Tier 4 across Part D plans, ranging from Tier 4 to Tier 4.
Does testosterone undecanoate 198 MG Oral Capsule [Jatenzo] require prior authorization?
100% of Part D formularies require prior authorization for testosterone undecanoate 198 MG Oral Capsule [Jatenzo]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on testosterone undecanoate 198 MG Oral Capsule [Jatenzo]?
In 2023, total Medicare Part D spending on testosterone undecanoate 198 MG Oral Capsule [Jatenzo] was $4,591,544, covering 1,079 beneficiaries. The average spend per beneficiary was $4,255.37.
Read our methodology - how this data is sourced, computed, and verified.